Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-cholesterol and slow atherosclerosis preventing cardiovascular events. While it is known that circulating PCSK9 enhances platelet activation (PA) and that PCSK9i reduce it, the underlying mechanism is not still c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cammisotto, Vittoria, Baratta, Francesco, Castellani, Valentina, Bartimoccia, Simona, Nocella, Cristina, D’Erasmo, Laura, Cocomello, Nicholas, Barale, Cristina, Scicali, Roberto, Di Pino, Antonino, Piro, Salvatore, Del Ben, Maria, Arca, Marcello, Russo, Isabella, Purrello, Francesco, Carnevale, Roberto, Violi, Francesco, Pastori, Daniele, Pignatelli, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267646/
https://www.ncbi.nlm.nih.gov/pubmed/34281247
http://dx.doi.org/10.3390/ijms22137193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267646/
https://www.ncbi.nlm.nih.gov/pubmed/34281247
http://dx.doi.org/10.3390/ijms22137193

Ejemplares similares